Silo Pharma Inc. (NASDAQ: SILO) announced a strategic expansion into artificial intelligence as a second line of business following its acquisition of assets from Qwikagents.ai, a platform designed to deploy autonomous AI agents for tasks including research, content generation, scheduling and workflow automation. The company said the move positions it to capitalize on a rapidly growing AI agent market projected to reach $47 billion to $53 billion by 2030, while it continues advancing its SPC-15 PTSD program toward an investigational new drug application submission and Phase 1 clinical trials, underscoring a dual focus on biopharmaceutical development and emerging AI-driven revenue opportunities.
According to the press release, Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
The acquisition of Qwikagents.ai assets marks a significant pivot for the company, which has primarily focused on biopharmaceuticals. The AI agent market is expected to grow substantially in the coming years, and Silo Pharma aims to leverage this trend to generate new revenue streams. The company did not disclose the financial terms of the acquisition.
For investors, this move could signal a diversification strategy that reduces reliance on the success of its drug development pipeline, which carries inherent risks and long timelines. By entering the AI space, Silo Pharma may attract a broader investor base interested in AI technologies. However, the company faces competition from established AI firms and must successfully integrate the new assets.
The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO. More details on the acquisition can be found in the full press release at https://ibn.fm/XJG64.
